Menu
Innovation Observatory > Reports > Drugs > KTE-C19 for relapsed or refractory mantle cell lymphoma

< Back

KTE-C19 for relapsed or refractory mantle cell lymphoma

Drugs

Cancer and Palliative Care

July 2017


KTE-C19 is a therapy where some of the patient’s blood cells are removed, engineered to contain a compound which targets and kills the lymphoma cells, and re-injected into the patient. It requires blood to be taken from the patient and then a single intravenous administration of treated cells, which may stay active in the body and reduce relapse.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts